BWE-11.19.20-reg-1

Thursday, November 19, 2020

6:00p - 8:00p (ET)
Registration is FREE*

Program Information

a97433ffcb4040ea9818744182cd9a58

“The current estimated annual cost to American society of just nine of the most common neurological diseases is staggering, totaling $789 billion. These conditions include Alzheimer’s disease and other dementias, low back pain, stroke, traumatic brain injury, migraine, epilepsy, multiple sclerosis, spinal cord injury, and Parkinson’s disease.”

Gooch CL, Pracht E, Borenstein AR. The burden of neurological disease in the United States: a summary report and call to action. Ann Neurol. 2017;81:479-484. doi:10.1002/ana.24897

Agenda

6:00p
-
6:50p
Next Generation Migraine Therapies
Faculty Larry Charleston IV, MD, MSc, FAHS

Migraine is a painful headache syndrome and is the second-most disabling neurological disorder worldwide, affecting 38 to 47 million Americans and costing more than $31 billion/year in the US alone. Nearly 1 in every 5 women and 6% of men in the US suffer from migraine, for a total of approximately 12% of the population. Migraine disorders range from low frequency episodic to chronic, have multiple associated symptoms from motor and sensory to cognitive and affective, and are a major cause of absentee days from work, decreased family and social activities, as well as direct and indirect healthcare costs. The majority of people with migraine receive care from primary care providers with a smaller proportion of patients receiving care from specialists and subspecialists. Evidence-based acute “abortives,” prophylaxis “preventive,” and psychological/behavioral “nonpharmacological” modalities and treatments exist. Yet, there remains an unmet need for abortive treatments. Moreover, prevention and nonpharmacological modalities are underutilized in people with migraine. Poorly optimized abortive treatment of episodic migraine is associated with an increased risk for these patients to develop chronic migraine (CM). Patients with CM have greater disability, work loss, lower income, reduced productivity at home, greater use of healthcare resources, and 4.4 times greater total medical cost than patients with episodic migraine. Recent FDA approved and cleared treatments for migraine highlight, in part, the complex pathophysiology of the disorder and offer more treatment options to help improve patient outcomes. This course will explore recent FDA approved/cleared abortive and preventive treatments for migraine with discussion and pearls for integrating these treatments into clinical practice. The target audience will include all healthcare professionals who are involved in treating patients with migraine with a special emphasis for those who practice primary care medicine, neurology, and headache medicine.

UAN 0530-0000-20-187-L01-P
AANP Pharmacology Hours Rx .10
6:50p
-
7:40p
Management of Relapsing-Remitting MS in a Changing Therapeutic Landscape
Faculty Michelle H. Cameron, MD, PT, MCR
Supported by an educational grants from Bristol Myers-Squibb and Novartis

Multiple sclerosis (MS) is the most common nontraumatic cause of disability in young adults and affects over 900,000 people in the US. Most people with MS have a relapsing remitting course of the disease, with recurring relapses of neurological symptoms and consequent accumulation of disability. The first disease modifying therapies (DMTs) to reduce the frequency of these relapses and the accumulation of disability became available almost 30 years ago. These therapies were only at best modestly effective, and all needed to be given by injection. Over the last decade MS DMTs for relapsing remitting MS (RRMS) have advanced substantially, with now over 20 DMTs available, ranging in efficacy, risk, and route of administration resulting in a complex treatment landscape for providers and for patients with MS. This presentation will start with a case study of a patient with RRMS followed by a brief overview of the course, epidemiology, and overall management of MS. There will be an in depth discussion of the MS DMTs with a focus on their evolution over time and approaches to selecting the ideal DMT together with our patients with RRMS. The target audience will include all healthcare professionals who are involved in treating patients with MS with a special emphasis for those who practice primary care medicine and neurology.

UAN 0530-0000-20-186-L01-P
AANP Pharmacology Hours Rx 0.50

Slides

Next Generation Migraine Therapies >> view slides

Management of Relapsing-Remitting MS in a Changing Therapeutic Landscape >> view slides

Program Guide

Click here to download the program guide for this webinar.

CE/CME and Accreditation

Next Generation Migraine Therapies

November 19, 2020
This activity is provided by Global Education Group.

Statement of Need/Program Overview

Migraine is a public health issue with serious social and economic costs.

Healthcare costs are 70% higher for a family with a migraine sufferer than a non-migraine affected family. Healthcare and lost productivity costs associated with migraine are estimated to be as high as $36 billion annually in the U.S. American employers lose more than 157 million workdays due to migraine each year. Beyond the burden of migraine itself, having migraine increases the risk for other physical and psychiatric conditions with the resulting increase in disability and healthcare costs. In 2015, the medical cost for treating chronic migraine was over $5.4 billion, however, these sufferers collectively spent over $41 billion treating their entire range of conditions.
-Migraine Research Foundation

Educational Objectives

  • Explain the goals of acute “abortive” and preventive migraine therapy

Faculty

Larry Charleston IV MD, MSC, FAHS
Headache Medicine Clinical Associate Professor,
Department of Neurology
Michigan Medicine
University of Michigan
Ann Arbor,MI

Physician Accreditation Statement

Global Education Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

* This CME/CE activity complies with all requirements of the federal Physician Payment Sunshine Act. If a reportable event is associated with this activity, the accredited provider managing the program will provide the appropriate physician data to the Open Payments database.

Physician Credit Designation

Global Education Group designates this live meeting for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Credit Designation

Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

This educational activity for 1.0 contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacist Continuing Education

Accreditation Statement

Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Credit Designation
Global Education Group designates this continuing education activity for 1.0 contact hour(s) (0.10 CEUs) of the Accreditation Council for Pharmacy Education.
(0530–0000–20–187–L01–P- .1 hour(s) pharmacology hours

This is a knowledge based activity.

Instructions to Receive Credit
lease look for an email from outcomes@globaleducationgroup.com that will be sent to you 1 week following this BRAINWeekEnd program. The email will have your personalized link to complete the online conference evaluation form needed to receive your CE/CME certificate. Upon completion of this form, you will be able to download, print, and save your certificate immediately! Please make sure to check your junk mail folder, as this email may be tagged as spam.

Nurse Practitioner Continuing Education

Global Education Group is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 110121. This activity is approved for 1.0 contact hour(s) (which includes 0.10 hour(s) of pharmacology).

Physician Assistants

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.0 hours of Category 1 credit for completing this program.

Management of Relapsing-Remitting MS in a Changing Therapeutic Landscape

November 19, 2020
This activity is provided by Global Education Group.

This activity is supported by an educational grant from Novartis and BMS.

Statement of Need/Program Overview

To achieve optimal outcomes for people with MS healthcare professionals (HCPs) would benefit from an update on new therapies for RRMS, strategies on how to create a collaborative treatment plan with people with MS, and updated recommendations on RRMS treatment choices and timing.

Educational Objectives

  • Summarize the new therapies available for patients with rrms and the therapies under investigation

    • Faculty

    Michelle H. Cameron MD, PT, MCR
    Associate Professor
    Department of Neurology
    Oregon Health & Science University
    Acting Chief of Neurology
    VA Portland Health Care System
    Co-Director and Associate Director for Research
    VA MS Center of Excellence
    West Portland, OR

    Physician Accreditation Statement

    Global Education Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    * This CME/CE activity complies with all requirements of the federal Physician Payment Sunshine Act. If a reportable event is associated with this activity, the accredited provider managing the program will provide the appropriate physician data to the Open Payments database.

    Physician Credit Designation

    Global Education Group designates this live meeting for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Nursing Credit Designation

    Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

    This educational activity for 1.0 contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Pharmacist Continuing Education

    Accreditation Statement

    Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

    Credit Designation
    Global Education Group designates this continuing education activity for 1.0 contact hour(s) (0.10 CEUs) of the Accreditation Council for Pharmacy Education.
    (0530-0000-20-186-L01-P - .1 credit hours)

    This is a This is a knowledge based activity.

    Instructions to Receive Credit
    lease look for an email from outcomes@globaleducationgroup.com that will be sent to you 1 week following this BRAINWeekEnd program. The email will have your personalized link to complete the online conference evaluation form needed to receive your CE/CME certificate. Upon completion of this form, you will be able to download, print, and save your certificate immediately! Please make sure to check your junk mail folder, as this email may be tagged as spam.

    Nurse Practitioner Continuing Education

    Nurse Practitioner Continuing Education Global Education Group is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 110121. This activity is approved for 1.0 contact hour(s) (which includes 0.50 hour(s) of pharmacology).

    Physician Assistants

    AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.0 hours of Category 1 credit for completing this program.

    Target Audience

    Healthcare providers who treat and manage neurologic conditions, including Internists, Neurologists, Nurse Practitioners, Primary Care Physicians, Psychiatrists, Physician Assistants.

    Global Contact Information

    For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

    Program Agenda

    12:00p - 12:50p — Next Generation Migraine Therapies
    12:50 - 1:00p — Faculty Q&A
    1:00p - 1:50p — Management of Relapsing-Remitting MS in a Changing Therapeutic Landscape

    System Requirements

    PC
    Microsoft Windows 2000 SE or above.
    Flash Player Plugin (v7.0.1.9 or greater)
    Internet Explorer (v5.5 or greater), or Firefox
    Adobe Acrobat Reader*

    MAC
    MAC OS 10.2.8
    Flash Player Plugin (v7.0.1.9 or greater)
    Safari
    Adobe Acrobat Reader*
    Internet Explorer is not supported on the Macintosh.

    Disclosure of Conflicts of Interest

    Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

    The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

    Larry Charleston—Nothing to disclose
    Michelle H. Cameron—Nothing to disclose

    The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

    Ashley Marostica, RN, MSN—Nothing to disclose Kristin Delisi, NP—Nothing to disclose Andrea Funk—Nothing to disclose Lindsay Borvansky—Nothing to disclose Liddy Knight—Nothing to disclose

    Disclosure of Unlabled Use

    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) does not recommend the use of any agent outside of the labeled indications.

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Evaluation and Application for Credit Form

    Please look for an email from Global Education Group that will be sent to you 24-48 hours following this BRAINWeekEND program. The email will have your personalized link to complete the online conference evaluation form needed to receive your CE/CME certificate. Upon completion of this form, you will be able to download, print, and save your certificate immediately! Please make sure to check your junk mail folder, as this email may be tagged as spam.

    © 2024 | info@brainweek.com